Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Michael Parini is Chief Legal Officer at Biogen. OQRO lists 1 transaction filed with the SEC under this name, the latest on Sep 3, 2026, each linked to the official Form 4.
Chief Legal Officer
Disclosures on record
1
Companies involved
1
BiogenBIIB
Sep 1, 20267,405disclosed Sep 3
DetailsOfficial recordMichael Parini has no open-market purchase on record since 2017. Sales in 5 of the 10 years since 2017.
Michael Parini reported 0 open-market purchases and 168 sales since 2017; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2021 | — | $3.71M15×15 trades |
| 2020 | — | $13.6M90×90 trades |
| 2019 | — | $11.9M42×42 trades |
| 2018 | — | $13.1M16×16 trades |
| 2017 | — | $3.08M5×5 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Michael Parini has no open-market purchase on record since 2017. Sales in 5 of the 10 years since 2017.
In SEC filings since 2017: no open-market purchase is on record; the latest open-market sale is from 2021.
Vertex Pharmaceuticals (VRTX), from 2017 to 2021: 0 purchases and 168 sales.
Michael Parini reported 0 open-market purchases and 168 sales here, 2017 to 2021.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.